Related Experiment Video
Updated: May 6, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Does NPHS1 polymorphism modulate P118l mutation in NPHS2?
Nida Dincel1, Sevgi Mir, Afig Berdeli
1Department of Pediatric Nephrology, Ege University Faculty of Medicine, Bornova, Izmir, Turkey.
Nephrotic syndrome in infants is rare. A 4-month-old with steroid-resistant nephrotic syndrome (NS) had NPHS1 and NPHS2 gene variations, suggesting potential genetic modifiers in pediatric NS.
Area of Science:
- Pediatric Nephrology
- Genetics
- Molecular Biology
Background:
- Nephrotic syndrome (NS) in the first year of life is uncommon and presents as a heterogeneous group of disorders.
- Mutations in the NPHS2 gene are associated with NS, typically manifesting between birth and 6 years of age.
Observation:
- A 4-month-old infant presented with steroid-resistant NS.
- This patient carried a polymorphism in the NPHS1 gene (E117K) and a mutation in the NPHS2 gene (P118L).
Findings:
- The patient exhibited a poor prognostic NPHS2 mutation.
- The presence of a polymorphic NPHS1 mutation (E117K) alongside the NPHS2 mutation raises questions about its potential role as a genetic modifier.
Implications:
- Investigating the E117K NPHS1 polymorphism's effect on podocyte signaling pathways is crucial.
- This case highlights the complexity of genetic factors in early-onset nephrotic syndrome and suggests potential genetic modifiers.
More Related Videos
Related Concept Videos
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Single Nucleotide Polymorphisms-SNPs
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Mutations

